Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk
Open Access
- 12 October 2004
- journal article
- research article
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 7 (4) , 333-337
- https://doi.org/10.1038/sj.pcan.4500753
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Association of V89L SRD5A2 Polymorphism With Prostate Cancer Development in a Japanese PopulationJournal of Urology, 2003
- The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis.Mutagenesis, 2002
- V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progressionUrology, 2001
- A polymorphism in theCYP17 gene is associated with prostate cancer riskInternational Journal of Cancer, 2000
- Hormonal Predictors of Prostate Cancer: A Meta-AnalysisJournal of Clinical Oncology, 2000
- Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2)Carcinogenesis: Integrative Cancer Research, 1999
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- Cancer statistics, 1998CA: A Cancer Journal for Clinicians, 1998
- Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17Human Molecular Genetics, 1994
- 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black malesThe Lancet, 1992